Feeds:
Posts
Comments

Archive for the ‘Brachytherapy’ Category

URO TODAY: Italian researchers have been studying the effectiveness of treating locally advanced prostate cancer with external beam radiation therapy combined with high-dose-rate brachytherapy as a boost. READ MORE>

Read Full Post »

DOMINION POST: Prostate cancer patients are being offered faster, more targeted and more effective treatment with the introduction of a high-dose radiation therapy at Wellington Hospital.

The technique, “high-dose-rate brachytherapy” uses small plastic tubes placed into the prostate and irradiating it from inside.

It will cut radiation treatment from seven to four weeks and is especially effective for advanced cases.

Waikato Hospital is the only other NZ centre to use the technique. READ MORE>

Read Full Post »

NEW PROSTATE CANCER INFOLINK: Either maximal androgen blockade or hormonal monotherapy are reasonable choices for use in combination with brachytherapy in the management of men with intermediate- or high-risk prostate cancer, a retrospective study finds. READ MORE>

[But]…this study is only a retrospective analysis of database information. A prospective, randomised clinical trial (which has never been carried out as far as we are aware) might demonstrate a different outcome.

Read Full Post »

URO TODAY: Forty percent of about 400 men treated with brachytherapy developed urinary obstructive symptoms, generally within the first three to six months, according to a study  of about 400 prostate cancer patients. READ MORE>

These symptoms resolved in a large proportion of men. Impaired potency occurred in 15% of men by six months and in more than 40% of men by 60 months. Bowel symptoms were less common and had a slower onset.

Read Full Post »

PR NEWSWIRE.COM: Compared with surgery, brachytherapy (radiation seed implants) is proving to have a superior disease-free survival rate for patients with early stage prostate cancer, according to two studies in the US. READ MORE> and HERE>

Read Full Post »

PR WEB: A combination of brachytherapy and intensity modulation radiation therapy can cure between 98% for low-risk patients, 95% for intermediate risk and 85% for high risk patients in expert hands, says a prostate cancer specialist with the Florida Radiation Oncology Group. READ MORE>

Read Full Post »

URO TODAY: Short-term urinary side effects after prostate brachytherapy are common, follow a predictable course, and typically resolve within one year, a new study concludes. READ MORE>

Conservative management of short-term urinary side effects is recommended to minimise the risk of long-term urinary complications.

Read Full Post »

URO TODAY: Quality of life two years after treatment for prostate cancer shows wide variability, according to a new study in Spain. READ MORE>

Radical prostatectomy had the largest negative impact on the sexual and urinary incontinence domains. Differences between external radiation and brachytherapy were relatively small. Brachytherapy led to a moderate increase in urinary irritation compared to the other two groups.

Read Full Post »

JULY 31: URO TODAY: Researchers have investigated whether whole-pelvis radiotherapy in combination with interstitial brachytherapy – thus covering the pelvic lymph nodes – improves treatment outcome in high-risk prostate cancer. READ MORE>

Read Full Post »

JULY 27: URO TODAY: A combination approach to hormone and radiation treatment for men with localised but high risk prostate cancer works better than so-called mono-therapy, a new study has found. READ MORE>

Men treated with external beam radiotherapy and brachytherapy, short-course androgen suppression therapy with a luteinizing hormone-releasing hormone (LHRH) agonist plus an anti-androgen, have decreased prostate cancer-specific mortality compared with mono-therapy with an LHRH agonist, the researchers report.

NEW PROSTATE CANCER INFOLINK: Another study (of about 200 patients) in Japan found combined androgen blockade with an LHRH) agonist + bicalutamide 80 mg had a small, marginally significant overall survival benefit compared to an LHRH agonist + a placebo (ie, LHRH agonist monotherapy) at a median follow-up of 5.2 years. READ MORE>

Read Full Post »

« Newer Posts - Older Posts »